<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052569</url>
  </required_header>
  <id_info>
    <org_study_id>RXDX-105 - EAP</org_study_id>
    <nct_id>NCT03052569</nct_id>
  </id_info>
  <brief_title>Expanded Access to RXDX-105 for Cancers With RET Alterations</brief_title>
  <official_title>Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ignyta, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ignyta, Inc.</source>
  <brief_summary>
    <textblock>
      Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations
      who have not received TKIs that target RET alterations, who do not qualify for participation
      in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <condition>Cancers With RET Alterations</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXDX-105</intervention_name>
    <description>Oral Capsules</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced cancer with RET alterations

          -  Unable to participate in an ongoing RXDX-105 clinical trial

          -  Willing and able to provide written, signed informed consent

          -  Medically suitable for treatment with RXDX-105

        Exclusion Criteria:

          -  Prior treatment with a TKI that has activity against RET alterations

          -  Currently enrolled in an ongoing clinical study with any other investigational agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Rupal Patel</last_name>
    <phone>(858) 332-0774</phone>
    <phone_ext>114</phone_ext>
    <email>rpatel@ignyta.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pratik S. Multani, MD, MS</last_name>
    <phone>(858) 332-0787</phone>
    <phone_ext>173</phone_ext>
    <email>pmultani@ignyta.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Www.Ignyta.Com</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>858-255-5959</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>February 10, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
